COVID-19 Therapeutics

When SARS-CoV-2 emerged in late 2019, there were no proven treatments for coronavirus infections. In vitro activity of chloroquine and hydroxychloroquine against SARS-CoV-2 generated enormous early enthusiasm, fueled by small uncontrolled French studies. Lopinavir-ritonavir, remdesivir, and interferon-beta were rapidly repurposed based on activity against SARS-CoV-1 or MERS-CoV. The unprecedented speed of the pandemic drove widespread off-label use of unproven therapies before evidence was available. The urgent need for rigorous clinical trials led to the rapid establishment of adaptive platform trials, most notably the UK RECOVERY trial, which would become the most impactful therapeutic trial in the pandemic.

The RECOVERY trial delivered the two most consequential findings of the pandemic. First, it definitively disproved hydroxychloroquine, showing no mortality benefit (rate ratio 1.09) and ending one of the largest therapeutic controversies. Then, in June 2020, RECOVERY demonstrated that dexamethasone 6mg daily for 10 days reduced 28-day mortality by one-third in ventilated patients (29.3% vs 41.4%) and by one-fifth in patients receiving oxygen (23.3% vs 26.2%). This was the first treatment proven to save lives in COVID-19 and remains the most impactful single result. Concurrently, the ACTT-1 trial showed remdesivir shortened recovery time from 15 to 10 days in hospitalized patients, though the mortality benefit was modest and inconsistent across later trials including WHO SOLIDARITY.

The therapeutic landscape expanded dramatically in 2021-2022. Nirmatrelvir-ritonavir (Paxlovid) demonstrated 89% reduction in COVID-19 hospitalization or death when given within 5 days of symptom onset in the EPIC-HR trial, becoming the first effective oral antiviral. Tocilizumab (RECOVERY, REMAP-CAP) and baricitinib (COV-BARRIER) were proven to reduce mortality when added to corticosteroids in patients with progressive disease requiring oxygen or ventilation, establishing the role of immunomodulation beyond dexamethasone alone. Monoclonal antibodies (sotrovimab, bebtelovimab) provided early treatment options but were progressively rendered ineffective by viral evolution. The treatment paradigm crystallized into a two-phase model: antivirals early in disease, immunomodulation for severe/progressive disease.

NIH and WHO COVID-19 treatment guidelines evolved rapidly to incorporate new evidence, with frequent updates reflecting the pace of trial results. Key recommendations crystallized around a severity-based treatment algorithm: for mild-moderate disease in high-risk patients, nirmatrelvir-ritonavir (Paxlovid) within 5 days of onset; for hospitalized patients requiring supplemental oxygen, dexamethasone; for patients with progressive disease on oxygen, add tocilizumab or baricitinib; for ventilated patients, dexamethasone with consideration of tocilizumab. Remdesivir was recommended for select hospitalized patients. Guidelines explicitly recommended against hydroxychloroquine, ivermectin, and convalescent plasma outside clinical trials.

As SARS-CoV-2 has transitioned to endemic circulation, the therapeutic focus has shifted. Paxlovid remains the mainstay of outpatient treatment for high-risk patients, though debates continue about the Paxlovid rebound phenomenon and benefit in vaccinated populations. Dexamethasone plus tocilizumab/baricitinib is the standard for severe hospitalized disease. The rapid therapeutic development during COVID-19 demonstrated the power of large adaptive platform trials and has permanently changed how we approach pandemic preparedness. Key lessons include the danger of adopting treatments based on in vitro data or small studies, the importance of randomized evidence even during emergencies, and the value of collaborative international trial infrastructure that can be activated rapidly for future threats.